Detalhe da pesquisa
1.
Metastatic ER+ Breast Cancer: Mechanisms of Resistance and Future Therapeutic Approaches.
Int J Mol Sci
; 24(22)2023 Nov 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-38003387
2.
Abemaciclib: The First FDA-Approved CDK4/6 Inhibitor for the Adjuvant Treatment of HR+ HER2- Early Breast Cancer.
Ann Pharmacother
; : 10600280211073322, 2022 Feb 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35135362
3.
New and emerging therapies for the treatment of relapsed/refractory diffuse large B-cell lymphoma.
J Oncol Pharm Pract
; 28(8): 1848-1858, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-35469489
4.
Amivantamab-Vmjw: A Novel Treatment for Patients with NSCLC Harboring EGFR Exon 20 Insertion Mutation after Progression on Platinum-Based Chemotherapy.
Biomedicines
; 11(3)2023 Mar 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-36979929
5.
Ocular toxicities associated with antibody drug conjugates and immunotherapy in oncology: clinical presentation, pathogenesis, and management strategies.
Expert Opin Drug Saf
; 22(10): 921-928, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37612255
6.
PARP Inhibitors for Breast Cancer: Germline BRCA1/2 and Beyond.
Cancers (Basel)
; 14(17)2022 Sep 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36077867
7.
Precision Genomic Practice in Oncology: Pharmacist Role and Experience in an Ambulatory Care Clinic.
Pharmacy (Basel)
; 8(1)2020 Mar 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32182657
8.
Evaluation of a Pharmacist Led Oral Chemotherapy Clinic: A Pilot Program in the Gastrointestinal Oncology Clinic at an Academic Medical Center.
Pharmacy (Basel)
; 8(1)2020 Mar 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-32244894